With launches, continuing momentum in India, other branded markets and a pick-up in the US, Ajanta would deliver 12% revenue/PAT growth each over FY22-24
India business is growing as per projections; whereas US business will bounce back soon.
It posted net profit of Rs.147.76 crores for the period ended June 30, 2020.
The companyreported total income of Rs.2915.67 crores during the 12 months period ended March 31, 2021
Biocon will be responsible for supplying Semaglutide to Ajanta for exclusive marketing in 23 countries and semi-exclusive marketing in 3 countries across Africa, Middle East and Central Asia
A pharma industry veteran with over three decades of experience in domestic as well as international markets
ICICI Direct gives a preview on the earnings narrative for Q3FY22
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
